Entera Bio Stock Forecast
NASDAQ: ENTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 12:17 PM ET
ENTX analyst consensus
Consensus (5 analysts)
strong_buy
Avg. price target
$9.75+293.15%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Entera Bio (2026-10-08), 5 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $9.75, with a high estimate of $11.00 and a low estimate of $9.00. The average target implies upside of 293.1% from the current price of $2.48.
The spread between the highest and lowest targets is 22.2%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ENTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 5 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $9.00 | +262.90% |
| Average target | $9.75 | +293.15% |
| High target | $11.00 | +343.55% |